January 13, 2015
GlaxoSmithKline K.K. (GSK) and Nippon Kayaku announced on January 9 that they will end their copromotion of GSK’s anticancer drug Tykerb (lapatinib). The initial goal of market penetration has been achieved, the two companies explained. They have agreed to end...read more